All In MedTech

Device Trial Radar · NCT07939581

Influence of SUPRA SDRM on the Healing of Chronic Wounds

The Influence of SUPRA SDRM on Wound Healing of Chronic Wounds: A Pilot Study

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Aug 16, 2023

Primary completion

Feb 27, 2025

Study completion Jun 5, 2025

Sponsor

Lead sponsor
Polymedics Innovations Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how SUPRA SDRM affects the healing of chronic wounds. SUPRA SDRM is a synthetic wound covering that slowly breaks down on the wound. The trial includes adults aged 18 to 80 with a leg or foot wound that has not healed for at least 3 months. As a small pilot trial, it helps plan larger trials. The main questions it aims to answer are: * How does the size of the wound change during 12 weeks of treatment? * How does the condition of the wound change? All participants receive SUPRA SDRM. There is no comparison group. Participants: * Receive SUPRA SDRM on their wound, changed once a week for up to 12 weeks * Visit the clinic weekly for wound photos, wound checks and wound measurements * Answer questions about their quality of life * Return for follow-up visits after 4 and 6 months

Conditions

  • Chronic Wound
  • Leg Ulcer
  • Venous Leg Ulcer
  • Diabetic Foot Ulcer

Interventions

  • SUPRA SDRMDevice

    CE-marked, fully synthetic, biodegradable wound matrix made of a lactide-based terpolymer. Applied to the cleansed wound, covered with a wound contact layer and a secondary dressing, and changed once weekly for up to 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Remaining Wound AreaTime frame: Baseline and weekly (every 7 ± 2 days) up to week 12
  2. Wound Characteristics Assessed by the Hollander Wound Evaluation Scale (HWES)Time frame: Baseline and weekly (every 7 ± 2 days) up to week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Coremed - Joanneum Research

    Graz, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.